The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Long-term follow-up of psilocybin-facilitated smoking cessation
Open accessAbstract
BACKGROUND: A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. OBJECTIVES: To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration. METHODS: The present report describes biologically verified smoking abstinence outcomes of the previous pilot study at ≥12 months, and related data on subjective effects of psilocybin. RESULTS: All 15 participants completed a 12-month follow-up, and 12 (80%) returned for a long-term (≥16 months) follow-up, with a mean interval of 30 months (range = 16-57 months) between target-quit date (i.e., first psilocybin session) and long-term follow-up. At 12-month follow-up, 10 participants (67%) were confirmed as smoking abstinent. At long-term follow-up, nine participants (60%) were confirmed as smoking abstinent. At 12-month follow-up 13 participants (86.7%) rated their psilocybin experiences among the five most personally meaningful and spiritually significant experiences of their lives. CONCLUSION: These results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking abstinence. The present study adds to recent and historical evidence suggesting high success rates when using classic psychedelics in the treatment of addiction. Further research investigating psilocybin-facilitated treatment of substance use disorders is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As previously noted, mindfulness practices facilitate behavioral change by enabling individuals to identify triggers and habitual responses, whereas psychedelic therapy can amplify this awareness, resulting in even deeper behavioral transformations [33].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Classic psychedelics, such as synthetic LSD and psilocybin, which is found in certain mushrooms, have shown promise as aids in psychotherapy e.g., for mood disorders and substance dependence [1, 5, 33].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There is emerging evidence from early phase trials of nicotine dependence (14)”
From Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use (2024) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Psilocybin-assisted psychotherapy (PAT) also appears to be safe and potentially efficacious for substance use disorders, based on early trials for nicotine and alcohol use disorders [14,15], with little evidence of harmful use in the community [16].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“Psilocybin occasioned mystical experiences are defined by acute feelings of unity, sacredness, a noetic quality, positive mood, transcendence of space/time, and ineffability (6), and have previously shown a significant association with successful psilocybinfacilitated smoking cessation outcomes at 6-month followup (11…”
Self-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 1×
“psilocybin-facilitated treatment of alcohol dependence (24), the present findings indicate that 5-HT2AR agonists may hold therapeutic potential in treating a variety of”
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citationPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 4×
“Consistent with previously published data (4), no participants reported an increase in bothersome visual”
InfluentialSelf-citationGriffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Self-citationMacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Self-citationValidation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637
Self-citationLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- World Health Organization, 2011, WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco
Cited by
Sorted by citations
Items 601–694 of 694
Chapter 20. Theories and Techniques of Couple Therapy
Lebow, J. L., & Garcia, R. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg20
Chapter 34. Psychotherapy and Cyberspace
Yellowlees, P., & Shore, J. H. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg34
Chapter 12. Dialectical Behavior Therapy
Sonley, A. K. I., Boritz, T. Z., & McMain, S. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg12
Chapter 10. Theory in Dialectical Behavior Therapy
Chapman, A. L., & Kaufman, E. A. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg10
Chapter 31. Psychotherapy With Trans and Gender Diverse People
McIntosh, C., & Brown, N. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg31
Chapter 18. Applications of Individual Supportive Psychotherapy to Specific Disorders
Winston, A., & Punko, D. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg18
Chapter 30. Psychotherapy With Bisexual Patients
Marcus, B. F. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg30
Chapter 24. South Asian Americans
Tummala–Narra, P., & Kanwal, G. S. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg24
Rolland, J. S., & Walsh, F. W. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg19
Chapter 11. Treatment Techniques in Dialectical Behavior Therapy
Swenson, C. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg11
Chapter 25. There Is No Such Thing as Latinx
Gaztambide, D. J. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg25
Chapter 16. Theory of Individual Supportive Psychotherapy
Lippert, C. N., Roberts, L. W., Winston, A., & Goldstein, M. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg16
Chapter 3. Techniques of Brief Psychodynamic Psychotherapy
Dewan, M. J., Weerasekera, P., Stormon, L., & Jackson, D. J. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg03
Chapter 23. Contextualizing Psychodynamic Psychotherapy With Asian Americans
Ueng-McHale, J. Y., & Chin, C. R. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg23
Chapter 27. Issues Arising in Psychotherapy With LGBTQ+ Patients
Drescher, J., & Fadus, M. C. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg27
Chapter 28. Psychotherapy With Lesbians
Moga, D. E., & Reading, R. A. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg28
Chapter 22. African Americans and Psychotherapeutic Treatment
Powell, D. R., & Hart, A. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg22
Chapter 29. Psychotherapy With Gay Men
McCommon, B. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg29
Bhatt-Mackin, S. M., McEpplan, A., Dobson, K. S., & Cottraux, J. A. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg09
Thompson, C. W., & Husain, M. I. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780192863607.003.0001
O uso de agentes psicodélicos no tratamento da dependência de álcool e tabaco: revisão integrativa
Borges, E. M. A., Barbosa, G. C., Araújo, A. M. C., de Moraes, M. N., & Nunes, J. R. (2023) · SMAD Revista Eletrônica Saúde Mental Álcool e Drogas (Edição em Português) · doi:10.11606/issn.1806-6976.smad.2022.183132
Mycotherapeutics Affecting Dopaminergic Neurotransmission to Exert Neuroprotection
Kim, S., Nadar, R. M., DeRuiter, J., Pathak, S., Ramesh, S., Moore, T., Agrawal, D. C., & Dhanasekaran, M. (2023) · Springer eBooks · doi:10.1007/978-981-19-9550-7_13
Phenylketonuria with mental retardation and valproate-induced hyperammonemia
Sterpu, D. (2020) · Romanian Journal of Psychiatry & Psychotherapy · doi:10.37897/rjpp.2020.4.5
Psychedelikagestützte Psychotherapie in der Behandlung depressiver Störungen
Becher, L., Nanni, F., & Koslowski, M. (2023) · Nervenheilkunde · doi:10.1055/a-2101-9358
Tetem, J., Fischmann, T., & Möller, T. J. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/ztyxh
Experiencias psicodélicas: fenomenología, potenciales terapéuticos y modelos explicativos
Chernoff, T., Kliger, B., & Venturini, D. H. (2023) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i160.463
Kolbman, N., Liu, T., Guzzo, P. R., Gilligan, J., Mashour, G. A., Vanini, G., & Pal, D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.26.554802
The Use of Illicit Drugs in Therapy: an Introduction
Ross, A., & Hawthorn, J. (2023) · Current Addiction Reports · doi:10.1007/s40429-023-00509-z
Medeiros, D. G. D. M. D. S. (2022) · doi:10.47749/t/unicamp.2022.1259324
Traitements psychédéliques et soins en addictologie
Dauré, C., & Mallet, L. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-77934-3.00069-x
Breeksema, J. J. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.912040905
Macedo-Bedoya, J., & Calvo-Bellido, F. (2024) · Lilloa · doi:10.30550/j.lil/1889 · Cited by 2
Zeifman, R. J. (2024) · doi:10.32920/26052859.v1 · Cited by 1
Psilocybin in the Management of Substance Use Disorders: A Summary of Current Evidence
Bourji, H. E., Farhat, A., Hamdan, Z., Satodiya, R. M., Shukla, R., & Hayek, S. E. (2024) · Current Psychopharmacologye · doi:10.2174/0122115560288779240628043307
Foldi, C. J., Liknaitzky, P., Williams, M. L., & Oldfield, B. J. (2024) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.24022012
Ferreira, A. S. M., Martindale, S., & Luke, D. P. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00368
Innovative pharmakologische Ansätze zur Behandlung von Suchterkrankungen
Mick, I., Müller, C. A., & Majić, T. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21074-7.00008-3
Pulido-Saavedra, A., Borelli, A., Kitaneh, R., Alrafayia, M., Khave, L. J., Funaro, M. C., Potenza, M. N., & Angarita, G. A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2446623
Tewfik, G., Adaralegbe, A., Gomez, S., Aziz, R., Chaudhry, F. A., Rodriguez-Correa, D. T., & Adaralegbe, D. O. (2024) · Trends in Anaesthesia and Critical Care · doi:10.1016/j.tacc.2024.101514
Furnell, M., & Gordon, W. V. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1008802 · Cited by 2
Carlisle, N. A., Bradley, M. K., Hendricks, P. S., & MacCarthy, S. (2025) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2024.09.018
Psychedelic Drugs as Treatment Agents
Yehuda, R., Lepow, L., Bonnano, P. A., Zaretsky, T. G., Antonio, J. H., & Jagodnik, K. M. (2025) · doi:10.1093/med/9780197640654.003.0074
Psychedelics for Substance Use Disorders: Updates for the Psychiatric Trainee
Wilseck, L., Chatha, P., Canale, L., Raval, D., & Weleff, J. (2025) · American Journal of Psychiatry Residents Journal · doi:10.1176/appi.ajp-rj.2025.200301
Totomanova, I., Haijen, E. C. H. M., Hurks, P. P. M., Ramaekers, J. G., & Kuypers, K. P. C. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.03.002
Bahceci, D., Siefried, K. J., Steele, M., Harrod, M., Bell, G., Barratt, M. J., Nicholas, C. R. N., Rodgers, A., Hendricks, P. S., Stauffer, C. S., et al. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112699 · Cited by 1
Is there mush-room to improve the environmental sustainability of psilocybin production?
Lanham, L., McTaggart, A. R., & Falconer, J. R. (2025) · Journal of CO2 Utilization · doi:10.1016/j.jcou.2025.103137
Gunten, M. V., Russell, T., Stirland, I., Parks, S., Jenkins, T. G., & Edwards, J. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.12.658958
Prolegomena to a Phenomenology of Psychedelic Experiences
Forde, D. (2025) · New Directions in Philosophy and Cognitive Science · doi:10.1007/978-3-031-95203-6_1
Psychedelics for the Treatment of Substance Use Disorders: A Narrative Review of the Literature
Marcus, O., & Rush, B. R. (2025) · Substance Use & Addiction Journal · doi:10.1177/29767342251351123
Mind molding psychedelic drugs could treat depression, and other mental illnesses
Olson, D. E. (2018) · The Conversation · doi:10.64628/aai.sdhj3n394
Psychedelics that Heal and Harm – Their Therapeutic and Recreational Use
Wani, F. A., & Wani, I. A. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1011593
Managing Co-occurring Substance use Problems in Eating Disorder Treatment
Dennis, A. B., Lamphere, B., & Pryor, T. L. (2025) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2025.08.009
Wopfner, A., Beck, T., & Penzenstadler, L. E. (2025) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000954
Hosford, S., & Austin-Robillard, H. (2025) · Contemporary Family Therapy · doi:10.1007/s10591-025-09766-8 · Cited by 2
Brett, J., Lea, T., Knock, E., Albert, S. M., Acheson, L. S., Siefried, K. J., & Job, S. (2025) · Addiction · doi:10.1111/add.70284
Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review
Liszka, P., Ogorek, A., Olejnik-Chlewicka, K. M., Puchalski, K., Zasiadła, M., Patrzykąt, K. M., Perediatkiewicz, J., Urbański, W., Łuczak, P. M., & Brodowski, J. (2025) · Cureus · doi:10.7759/cureus.99942
Suggested Guidelines for Applying a Systemic Lens to Psychedelic-Assisted Psychotherapy
Lappan, S. N., & Davis, S. D. (2025) · Psychedelic Medicine · doi:10.1177/28314425251404021 · Cited by 2
Houff, J., Williams, A., Allen, O., Gisabella, B., Pantazopoulos, H., & Arco, A. D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.22.696123
Exploring self-reported health behavior change following naturalistic psychedelic use
de Carvalho, L. L., Encantado, J., Moller, A. C., Cornelius, T. M., Marrouch, N., Johnson, M. W., Garcia‐Romeu, A., Veiga, D., & Teixeira, P. J. (2025) · Journal of Health Psychology · doi:10.1177/13591053251392867
Self-citationPerceptions of Psilocybin-Assisted Psychotherapy and Standard Interventions for Nicotine Cessation
Kamilar-Britt, P., Oliva, A. B., & Earleywine, M. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2607724
Lifetime MDMA use and associations with meaning in life in the context of childhood trauma
Olofsson, M., Acar, K., Simonsson, O., Bragesjö, M., White, T., Almeida, R., Petrović, P., & Lebedev, A. V. (2026) · Scientific Reports · doi:10.1038/s41598-026-37721-6
Rose, J. R. (2026) · Springer eBooks · doi:10.1007/978-3-032-09377-6_10
Hallucinogenic Therapy in Alzheimer’s Disease targeting Mitochondria-Associated Membranes
Minauro‐Sanmiguel, F., & Vargas-Pérez, H. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.02.028
Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsPreprint
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. J. (2026) · eLife · doi:10.7554/elife.104006.2
The Online Attention to Spiritual Health Research: An Altmetric Analysis
Saberi, M. K., Mokhtari, H., Ahangari, S. A. H., Ouchi, A., & Shourcheh, B. (2026) · THE NEW ARMENIAN MEDICAL JOURNAL · doi:10.56936/18290825-2026.20v.2-108
Predictors of the Effectiveness of Psychedelics in Treating Depression—A Scoping Review
Chmiel, J., & Rybakowski, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052202 · Cited by 1
Maffeo, M. L. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009322348.009
Wood, B. J., Vest, M. F., Carfagno, C., Bartley, K. R., Sharma, P., Halberstadt, A. L., Blough, B. E., & Murnane, K. S. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00484
Henningfield, J. E., Barrett, F. S., Evans, S. M., Garcia‐Romeu, A., Garrett, B. E., Hienz, R. D., Lukas, S. E., Nayak, S. M., Strain, E. C., Weerts, E. M., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251398801
Self-citationPsilocybin: Chemical Foundations and Emerging Therapeutic Potential
Patil, S. A., & Hunsberger, H. C. (2026) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575429775260119043318 · Cited by 1
Skalski, P., Pękacka‐Falkowska, K., Pluto-Prądzyńska, A., & Owecki, M. K. (2026) · Brain Sciences · doi:10.3390/brainsci16040358
Meshkat, S., Jha, M. K., & Bhat, V. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20250043
Khosravi, M., Berardis, D. D., & Tusconi, M. (2026) · Mental Wellness · doi:10.4081/mw.2026.40
Penzenstadler, L. E., Brakha, T. A., & ZULLINO, D. F. (2026) · Suchttherapie · doi:10.1055/a-2599-1389
Can Childhood be Used as a Model to Understand the Effects of Psychedelics?
Hurwitz, E. S., Dean, J. G., & Walker, C. M. (2026) · Topics in Cognitive Science · doi:10.1111/tops.70058
Houff, J., Williams, A., Allen, O., Gisabella, B., Pantazopoulos, H., & Arco, A. D. (2026) · European Journal of Neuroscience · doi:10.1111/ejn.70574
Mutukula, S., Gagne-Hatfield, T., & Dunbar, Z. R. (2026) · Medicines · doi:10.3390/medicines13020019
Ten practical suggestions for setting up a psychedelic study
Caulfield, A., Butler, M., & Mehta, M. A. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261458350
van Dalen, F., Tap, S. C., Venema, S. D., Schellekens, Schoevers, R. A., & Spoelstra, S. K. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2685514
The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review
Ferreira, F. G. D. P., Fernandes, J. A. B., Filev, R., da Silveira, D. X., & Fidalgo, T. M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261453850
Pasquini, L., Vohryzek, J., Escrichs, A., Perl, Y. S., Ponce‐Alvarez, A., Idesis, S., Girn, M., Roseman, L., Mitchell, J., Gazzaley, A. H., et al. (2026) · Human Brain Mapping · doi:10.1002/hbm.70596 · Cited by 8
Heshmati, J., Grover, K., Mahmoodianfard, S., Rashwan, A., Sediqi, A., & Mir, H. (2026) · Addictive Behaviors · doi:10.1016/j.addbeh.2026.108803
Cellular mechanisms of serotonergic psychedelics - apical hypercontextualisation
Kaup, K., Jiménez, J. H., & Aru, J. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106876
Potential Role of Psychedelics in the Treatment of Depressive Disorder
Wang, S., & Bahk, W.-M. (2026) · Springer eBooks · doi:10.1007/978-981-92-1331-3_12
Klassische Halluzinogene in der Behandlung von Suchterkrankungen – Ein narrativer Überblick
Kippe, Y. D., Poppe, C. J., Repantis, D., & Majić, T. (2026) · Suchttherapie · doi:10.1055/a-2596-8400
Fletcher, K., Freestone, J., Ezard, N., Knock, E., & Siefried, K. J. (2026) · Current Addiction Reports · doi:10.1007/s40429-026-00783-7
Gawłowska, K., Nowakowska, K., Makówka, J., Bajurny, W., Góral, M. P., Bocheńska, A., Kopecki, S. D., Grodzińska, W., & Chłopaś-Konowałek, A. (2026) · Molecules · doi:10.3390/molecules31173130
Mechanistic Basis for 5-HT2AR Over 5-HT2BR Activation
Tang, L., Ji, X., Wang, Y., Cao, D., Li, H., He, L., Cheng, J., & Wang, S. (2026) · Nature Communications · doi:10.1038/s41467-026-77659-x
Ehrenkranz, R. C., Sepeda, N. D., Goldy, S. P., Weiss, B., Tiwari, P., Azimi, A., & Yaden, D. B. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261473405
Psychedelic-assisted therapy research for people with HIV
Vergel, N., & Saberi, P. (2026) · The Lancet HIV · doi:10.1016/s2352-3018(26)00227-4
Jones, J. L., Redding, J., & Amador, E. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261488486
Lewis, B. R., Garland, E. L., Schwartz, Z., Xin, Y., Byrne, K., & Brent, K. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100041
Sustained antidepressant-like effects of psychedelics through 5-HT2AR–β-arrestin signaling
He, L., Tang, L., Cao, D., Duan, W., Yu, J., Zhang, P., Li, H., Wang, Y., Meng, B., Wang, H., et al. (2026) · Nature Neuroscience · doi:10.1038/s41593-026-02497-5
Metadata
- Authors
- Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Corresponding author
- Johnson, Matthew W.
- Venue
- The American Journal of Drug and Alcohol Abuse
- Publisher
- Informa UK Limited
- Published
- 2016-07-21
- Volume
- 43
- Issue
- 1
- Pages
- 55-60
- ISSN
- 0095-2990 (ISSN-L)
- 1097-9891
- PMC
- PMC5641975
- OpenAlex
- W2506717582
- Cited by
- 696
- References
- 23
- Citations by year
- 2026: 53 · 2025: 100 · 2024: 89 · 2023: 112 · 2022: 131 · 2021: 63 · 2020: 83 · 2019: 17 · 2018: 31 · 2017: 13 · 2016: 3
- FWCI
- 17.16
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-01-20)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The American Journal of Drug and Alcohol Abuse (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (R01DA003889)
- Beckley Foundation (N/A)
- Heffter Research Institute (N/A)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- psilocybin, smoking cessation, smoking abstinence, long-term follow-up, cognitive behavioral therapy, classic psychedelics, addiction treatment, spiritual experience
- MeSH terms
- Combined Modality Therapy, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Pilot Projects, Psilocybin, Cognitive Behavioral Therapy, Smoking Cessation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
